Gates Invest in Immunocore Limited
A recent investment by Bill and Melinda Gates will assist Immunocore Limited, the largest TCR company in the world, in their development of soluble TCR-based therapeutics for infectious diseases. According to GlobeNewswire, the up to $40 million investment will not only help cover a greater percent of the affected population, but will help further develop ImmTAB and ImmTAV, molecules used in treating tuberculosis (TB) and human immunodeficiency virus (HIV).
11th Annual Prix Galien USA Awards Ceremony
This year’s Prix Galien Awards will be held on October 26th at the American Museum of Natural History. This annual ceremony recognizes outstanding biomedical and technology product achievement that improves the human condition. Some of the nominees for Best Biotechnology Product include industry giants like Genentech, Pfizer, and Boehringer Ingelheim while nominees for Best Pharmaceutical Agent include AbbVie, Novartis, and more. Former president Jimmy Carter will join the festivities as he was selected as this year’s Prix Galien Pro Bono Humanum Honoree.
ThromboGenics NV Aquires Jetrea
Jetrea, the only pharmacological treatment for symptomatic vitromacular adhesion (VMA) in the U.S., and vitromacular traction (VMT) in Europe, is switching owners. According to GlobeNewswire, ThromboGenics NV recently announced they will obtain the brand from Alcon, a Novartis company. ThromboGenics NV is a biotechnology company specializing in the treatment of retinal disorders, specifically diabetic eye disease. Launched in 2013, Jetrea now reaches 30,000 patients in 20 countries, and is approved in another 54.
Finn Partners Creates Health and Social Impact Specialty Group
Marketing and communications agency, Finn Partners, recently announced that Amy Terpeluk, Senior Partner, CSR & Social Impact, and Gil Bashe, Finn Partners Health Practice Managing Partner, will lead their new specialty group, “Health and Social Impact.” The group will enhance social responsibility in the Health Sciences. In relation to the new group, Bashe states, “When health executives speak to issues outside of day-to-day business interests, the world takes notice. It’s time for pharma to take its rightful place alongside major consumer products and finance and technology companies as leaders who convey how ideas, expertise, and abilities can fuel needed change.”
Teva’s $1.4 Billion Sale
In addition to their recent Paragard (intrauterine copper contraceptive) sale of $1.1 billion, Teva now has partnered with two other companies to sell their remaining specialty global women’s health business assets. According to Business Wire, CVC Capital Partners and Foundation Consumer Healthcare will acquire these assets in two separate deals for a combined total of around $1.4 billion. Teva plans to use the proceeds from the combined three deals for department repayment. Interim Teva CEO, Dr. Yitzhak Peterburg, said in a statement, “This demonstrates Teva’s commitment to delivering on our promise to generate net proceeds of at least $2 billion from the divestiture of non-core assets.”
UDG Acquires MicroMass
MicroMass Communications, the U.S.-based healthcare communications agency that specializes in behavioral change, was recently acquired by Ireland-based UDG Healthcare for $75.8 million, $63.8 million of which is initial consideration, and up to $12 million over the next three years, pending success of mutual profit goals.